Kura Oncology (NASDAQ:KURA) Stock: Insider Troy Edward Wilson Purchases 98,881 Shares

Kura Oncology, Inc. (NASDAQ:KURA – Get Free Report) CEO Troy Wilson acquired 98,881 shares of the business’s stock in a transaction on Friday, November 13th. The stock was bought at an average cost of $7.63 per share, for a total transaction of $754,462.03. Following the completion of the transaction, the chief executive officer directly owned 534,337 shares of the company’s stock, valued at $4,076,991.31. This trade represents a 22.71% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Troy Edward Wilson also recently made the following trade(s):

  • On Monday, November 16th, Troy Wilson acquired 101,119 shares of Kura Oncology stock. The shares were bought at an average price of $7.42 per share, for a total transaction of $750,302.98.
  • On Monday, August 24th, Troy Wilson bought 100,000 shares of Kura Oncology stock. The stock was bought at an average cost of $12.39 per share, with a total value of $1,239,000.00.

Kura Oncology Trading Up 5.6%

Shares of NASDAQ KURA opened at $7.49 on Wednesday. The company has a quick ratio of 3.56, a current ratio of 3.60 and a debt-to-equity ratio of 0.07. Kura Oncology, Inc. has a 1-year low of $6.75 and a 1-year high of $13.90. The business has a 50-day moving average of $9.95 and a 200-day moving average of $9.76.

Kura Oncology (NASDAQ:KURA – Get Free Report) last announced its earnings results on Tuesday, November 10th. The company reported ($0.78) EPS for the quarter, beating the consensus estimate of ($0.82) by $0.04. The business had revenue of $22.84 million for the quarter, compared to the consensus estimate of $24.94 million. Kura Oncology had a negative return on equity of 336.24% and a negative net margin of 369.26%. As a group, equities analysts anticipate that Kura Oncology, Inc. will post -3.20 EPS for the current year.

Institutional Trading of Kura Oncology

A number of institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. acquired a new stake in shares of Kura Oncology in the second quarter valued at $115,286,000. Bank of America Corp DE bought a new stake in Kura Oncology in the second quarter worth about $12,735,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Kura Oncology in the 2nd quarter valued at about $10,927,000. Aberdeen Group plc acquired a new stake in Kura Oncology in the 3rd quarter valued at about $8,443,000. Finally, Man Group plc acquired a new stake in Kura Oncology in the 2nd quarter valued at about $4,749,000.

Analyst Upgrades and Downgrades

Several analysts have issued reports on KURA shares. Barclays set a $24.00 price objective on shares of Kura Oncology in a research report on Wednesday, October 14th. Morgan Stanley set a $24.00 price target on shares of Kura Oncology in a report on Monday, August 24th. Citizens Jmp reaffirmed a “market outperform” rating and set a $24.00 price target on shares of Kura Oncology in a report on Monday, August 24th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Kura Oncology in a research note on Wednesday, October 14th. Finally, Wedbush boosted their price objective on shares of Kura Oncology from $36.00 to $38.00 and gave the stock an “outperform” rating in a report on Thursday, August 13th. Eleven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $25.88.

Read Our Latest Report on KURA

About Kura Oncology

(Get Free Report)

Kura Oncology is a biopharmaceutical company focused on developing precision medicines for cancer. Its research has centered on therapies that target molecular pathways involved in tumor growth and blood cancers. The company’s best-known program is ziftomenib, an oral menin inhibitor developed for acute myeloid leukemia, including forms associated with NPM1 mutations or KMT2A rearrangements. Kura has also worked on other targeted cancer therapies. Based in San Diego, California, Kura conducts drug development and clinical research in the United States and has worked with international partners to advance its programs.

See Also

Insider Buying and Selling by Quarter for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.